Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,140.22
(
0.52%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.63
(
2.37%
)
Bitcoin
74,532.90
(
-0.42%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Preciouslife1

Send PM Follow Ignore
Followers 90
Posts 20280
Boards Moderated 3
Alias Born 11/05/2005

Preciouslife1

Re: DewDiligence post# 68591

Monday, 11/24/2008 8:30:16 AM

Monday, November 24, 2008 8:30:16 AM

Post# of 257253
King Will Acquire Alpharma for $1.6 Billion, Gain Pain Drug
http://www.bloomberg.com/apps/news?pid=20601110&sid=a0eWEqYNW7C4
By Robert Greene

Nov. 24 (Bloomberg) -- King Pharmaceuticals Inc. will acquire the pain-drug developer Alpharma Inc. for $1.6 billion.

King will pay $37 a share in cash for Alpharma in a deal the boards of both companies approved, according to a statement from both companies distributed today by PR Newswire.

To contact the reporter on this story: Robert Greene in Washington at rgreene2@bloomberg.net.

Last Updated: November 24, 2008 08:05 EST

UPDATE 1-King Pharma to acquire Alpharma for about $1.6 bln
http://www.reuters.com/article/marketsNews/idINN2450242820081124?rpc=44&sp=true
Mon Nov 24, 2008 8:23am EST

BOSTON, Nov 24 (Reuters) - Drugmaker King Pharmaceuticals Inc (KG.N: Quote, Profile, Research, Stock Buzz) said on Monday it has agreed to acquire Alpharma Inc (ALO.N) for about $1.6 billion.

King's offer of $37 a share has been accepted by Alpharma's board and represents a premium of 10.4 percent over Alpharma's closing share price on Friday of $33.50.

King said it expects the transaction to add to its earnings per share, excluding one-time items, in the second full year following completion of the transaction, which it expects to occur by the end of this year.

King said it expects to achieve cost savings of $50 million to $70 million over the same period, mainly derived from general and administrative cost cuts and research and development savings achieved by avoiding the expense of new sales representatives for the launch of their new pain drug.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now